Barclays Raises Intuitive Surgical (ISRG) Price Target to $500
Key Points
- Barclays maintained an Overweight rating on Intuitive Surgical, Inc. on October 21, 2026, and lifted its price target to $500.00 from $485.00.
- Barclays's $500 price target implies 17.73% upside from Intuitive Surgical, Inc.'s ($ISRG) current $424.71 share price.
- The medical device maker recently reported trailing twelve month revenue of $11.03 billion alongside strong profit margins and double-digit revenue growth.
- Wall Street maintains a general buy consensus on the stock, with 30 analyst opinions guiding a mean price target of $478.53.
Get Intuitive Surgical text alerts
We text you when insiders, Congress, analysts or big funds move on $ISRG.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Intuitive Surgical, Inc. alert may contain errors. Disclosures
On October 21, 2026, Barclays maintained its Overweight rating on Intuitive Surgical, Inc. (NasdaqGS: ISRG) while raising its price target to $500.00 from $485.00. The research note arrived as Wall Street firms updated their views on the medical device maker following recent financial figures. Shares of Intuitive Surgical closed at $438.00 on October 20, 2026, and recently traded around $424.71, putting them down about 3.0% since that close.
ISRG
Intuitive Surgical, Inc.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Barclays's Call on Intuitive Surgical
In its October 21, 2026 note, Barclays kept an Overweight rating on the shares and bumped up its target price to $500.00 from $485.00. Other firms also weighed in on the same day. Evercore ISI Group maintained an In-Line rating with a target of $385.00, down from $400.00. Wells Fargo kept an Overweight rating and trimmed its target from $487.00 to $486.00. TD Cowen reiterated a Buy rating with an unchanged target of $485.00. RBC Capital maintained an Outperform rating while lowering its target from $575.00 to $550.00.
Intuitive Surgical, Inc. Stock Down 0.5%
The stock recently changed hands around $424.71 as of October 21, 2026, sitting below its 200-day moving average of $438.97 but above its 50-day moving average of $392.76. The company carries a market capitalization of roughly $153.03 billion and a P/E ratio of 48.95 based on recent earnings.
$ISRG price target
Intuitive Surgical, Inc. daily closes and this analyst's $500 target. Not advice.
Recent Earnings
Intuitive Surgical reported trailing twelve month revenue of $11.03 billion with trailing earnings per share of $8.85. The company posted a year-over-year revenue growth rate of 18.5%, supported by a net profit margin of 28.4% and a return on equity of 17.4%. These results underpin the ongoing demand for its robotic surgical systems and hospital equipment globally.
Dividend
Intuitive Surgical does not pay a dividend, retaining its earnings to fund research, development, and expansion of its minimally invasive care technologies.
Insider Buying and Selling at Intuitive Surgical, Inc.
Company insiders executed several sales in late summer. Officer Mark Preston Brosius sold 154 shares on August 21, 2026, for $59,439.00; 69 shares on September 9, 2026, for $24,671.00; and 48 shares on September 11, 2026, for $17,141.00. Additionally, officer Fredrik Widman sold 1,089 shares at $374.44 per share on September 15, 2026, for a total value of $407,765.00.
About Intuitive Surgical, Inc.
Headquartered in Sunnyvale, California, Intuitive Surgical develops and markets advanced tools that help doctors perform minimally invasive procedures. Its flagship technology assists surgeons in hospitals worldwide, driving steady demand across the healthcare sector.
Bottom Line
Barclays's updated price target reflects confidence in the company's growth trajectory despite recent share price movements. Investors will monitor upcoming financial reports and institutional filing updates for further signs of sector momentum.
Related Filing Alerts
Source: Barclays's rating change on $ISRG (Oct 21, 2026). Written by software, not financial advice. How we make alerts